BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kukkonen JP. Orexin/Hypocretin Signaling. Curr Top Behav Neurosci 2017;33:17-50. [PMID: 27909990 DOI: 10.1007/7854_2016_49] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Couvineau A, Voisin T, Nicole P, Gratio V, Blais A. Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions. World J Gastroenterol 2021; 27(44): 7582-7596 [PMID: 34908800 DOI: 10.3748/wjg.v27.i44.7582] [Reference Citation Analysis]
2 Mohammadi S, Dolatshahi M, Zare-shahabadi A, Rahmani F. Untangling narcolepsy and diabetes: Pathomechanisms with eyes on therapeutic options. Brain Research 2019;1718:212-22. [DOI: 10.1016/j.brainres.2019.04.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
3 Couvineau A, Voisin T, Nicole P, Gratio V, Abad C, Tan YV. Orexins as Novel Therapeutic Targets in Inflammatory and Neurodegenerative Diseases. Front Endocrinol (Lausanne) 2019;10:709. [PMID: 31695678 DOI: 10.3389/fendo.2019.00709] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
4 Liu C, Xue Y, Liu MF, Wang Y, Chen L. Orexin and Parkinson's disease: A protective neuropeptide with therapeutic potential. Neurochem Int 2020;138:104754. [PMID: 32422324 DOI: 10.1016/j.neuint.2020.104754] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Zhou F, Yan XD, Wang C, He YX, Li YY, Zhang J, Wang ZJ, Cai HY, Qi JS, Wu MN. Suvorexant ameliorates cognitive impairments and pathology in APP/PS1 transgenic mice. Neurobiol Aging 2020;91:66-75. [PMID: 32224066 DOI: 10.1016/j.neurobiolaging.2020.02.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
6 Liu MF, Xue Y, Liu C, Liu YH, Diao HL, Wang Y, Pan YP, Chen L. Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson's Disease. Front Neurosci 2018;12:835. [PMID: 30524223 DOI: 10.3389/fnins.2018.00835] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
7 Jin N, Zhu SY, Yang XY, Zhen C, Li Y, Zhang HH, Xu AP, Wang MY, Zheng C. Orexin-A potentiates glycine currents by activating OX1R and IP3/Ca2+/PKC signaling pathways in spinal cord ventral horn neurons. Brain Res Bull 2021;169:196-204. [PMID: 33515654 DOI: 10.1016/j.brainresbull.2021.01.017] [Reference Citation Analysis]
8 Chrobok L, Jeczmien-Lazur JS, Bubka M, Pradel K, Klekocinska A, Klich JD, Ridla Rahim A, Myung J, Kepczynski M, Lewandowski MH. Daily coordination of orexinergic gating in the rat superior colliculus-Implications for intrinsic clock activities in the visual system. FASEB J 2021;35:e21930. [PMID: 34533886 DOI: 10.1096/fj.202100779RR] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Radnikow G, Feldmeyer D. Layer- and Cell Type-Specific Modulation of Excitatory Neuronal Activity in the Neocortex. Front Neuroanat 2018;12:1. [PMID: 29440997 DOI: 10.3389/fnana.2018.00001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 9.3] [Reference Citation Analysis]
10 Anderson RI, Moorman DE, Becker HC. Contribution of Dynorphin and Orexin Neuropeptide Systems to the Motivational Effects of Alcohol. Handb Exp Pharmacol 2018;248:473-503. [PMID: 29526023 DOI: 10.1007/164_2018_100] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
11 Sadat-Shirazi MS, Soltani H, Nikpour N, Haghshenas M, Khalifeh S, Mokri A, Zarrindast MR. Alteration of orexin-A and PKCα in the postmortem brain of pure-opioid and multi-drug abusers. Neuropeptides 2020;83:102074. [PMID: 32741526 DOI: 10.1016/j.npep.2020.102074] [Reference Citation Analysis]
12 Costa A, Monti J, Torterolo P. Hypocretin (orexin) immunoreactivity in the feline midbrain: Relevance for the generation of wakefulness. J Chem Neuroanat 2020;105:101769. [PMID: 32145304 DOI: 10.1016/j.jchemneu.2020.101769] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Becquet L, Abad C, Leclercq M, Miel C, Jean L, Riou G, Couvineau A, Boyer O, Tan YV. Systemic administration of orexin A ameliorates established experimental autoimmune encephalomyelitis by diminishing neuroinflammation. J Neuroinflammation 2019;16:64. [PMID: 30894198 DOI: 10.1186/s12974-019-1447-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
14 Bian H, Huang L, Li B, Hu Q, Liang X, Tang J, Zhang JH. The arousal effect of hyperbaric oxygen through orexin/hypocretin an upregulation on ketamine/ethanol-induced unconsciousness in male rats. J Neurosci Res 2020;98:201-11. [PMID: 30895638 DOI: 10.1002/jnr.24414] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Lessel U, Ferrara M, Heine N, Marelli C, Carrettoni L, Pfau R, Schmidt E, Riether D. Identification of Highly Selective Orexin 1 Receptor Antagonists Driven by Structure-Based Design. J Chem Inf Model 2021;61:5893-905. [PMID: 34817173 DOI: 10.1021/acs.jcim.1c01055] [Reference Citation Analysis]
16 Alain C, Pascal N, Valérie G, Thierry V. Orexins/Hypocretins and Cancer: A Neuropeptide as Emerging Target. Molecules 2021;26:4849. [PMID: 34443437 DOI: 10.3390/molecules26164849] [Reference Citation Analysis]
17 [DOI: 10.1101/2021.02.20.432093] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Liu MF, Xue Y, Liu C, Liu YH, Diao HL, Wang Y, Pan YP, Chen L. Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson's Disease. Front Neurosci 2018;12:835. [PMID: 30524223 DOI: 10.3389/fnins.2018.00835] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Thompson MD, Sakurai T, Rainero I, Maj MC, Kukkonen JP. Orexin Receptor Multimerization versus Functional Interactions: Neuropharmacological Implications for Opioid and Cannabinoid Signalling and Pharmacogenetics. Pharmaceuticals (Basel) 2017;10:E79. [PMID: 28991183 DOI: 10.3390/ph10040079] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
20 Liu C, Xue Y, Liu M, Wang Y, Liu Z, Diao H, Chen L. Orexins increase the firing activity of nigral dopaminergic neurons and participate in motor control in rats. J Neurochem 2018;147:380-94. [DOI: 10.1111/jnc.14568] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
21 Liguori G, Tafuri S, Miyoshi C, Yanagisawa M, Squillacioti C, De Pasquale V, Mirabella N, Vittoria A, Costagliola A. Localization of orexin B and orexin-2 receptor in the rat epididymis. Acta Histochem 2018;120:292-7. [PMID: 29496265 DOI: 10.1016/j.acthis.2018.02.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
22 Sieminski M, Szypenbejl J, Partinen E. Orexins, Sleep, and Blood Pressure. Curr Hypertens Rep. 2018;20:79. [PMID: 29992504 DOI: 10.1007/s11906-018-0879-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
23 Xue T, Wu X, Chen S, Yang Y, Yan Z, Song Z, Zhang W, Zhang J, Chen Z, Wang Z. The efficacy and safety of dual orexin receptor antagonists in primary insomnia: A systematic review and network meta-analysis. Sleep Med Rev 2021;61:101573. [PMID: 34902823 DOI: 10.1016/j.smrv.2021.101573] [Reference Citation Analysis]